CCNE1 expression in high grade serous carcinoma does not correlate with chemoresistance
Metrics: PDF 473 views | HTML 1338 views | ?
Stav Sapoznik1,*, Sarit Aviel-Ronen2,3,4,*, Keren Bahar-Shany1, Oranit Zadok2 and Keren Levanon1,3,4
1Sheba Cancer Research Center, Chaim Sheba Medical Center, Ramat Gan 52621, Israel
2Department of Pathology, Chaim Sheba Medical Center, Ramat-Gan 52621, Israel
3The Talpiot Medical Leadership Program, Chaim Sheba Medical Center, Ramat Gan 52621, Israel
4Sackler Faculty of Medicine, Tel-Aviv University, Ramat Aviv 69978, Israel
*These authors have contributed equally to this work
Keren Levanon, email: firstname.lastname@example.org
Keywords: CCNE1, ovarian cancer, predictive biomarker, chemoresistance, neoadjuvant chemotherapy
Received: February 22, 2017 Accepted: May 23, 2017 Published: July 15, 2017
Delayed diagnosis of ovarian cancer, as well as high recurrence rates and lack of personalized therapy options, are among the causes for poor survival figures. Much effort is made towards developing new therapeutic possibilities, however predictive biomarkers are still unavailable. CCNE1 amplification, occurring in ~20% of the high grade serous ovarian tumors, was previously proposed as a marker for platinum resistance and poor prognosis as well as for CDK2 inhibition. The current study aimed to examine the role of CCNE1 positive-immunostain as a predictor of first-line taxane-platinum chemoresistance. We evaluated matched pre- vs. post-neoadjuvant chemotherapy tumor samples and correlated the degree of pathological response to treatment with CCNE1 expression levels. Our results indicate that CCNE1 immunohistochemistry does not predict taxane-platinum chemoresistance in ovarian cancer patients. Further research is required in order to enable personalized adjuvant treatment, in cases where poor pathological response is achieved after the neoadjuvant phase.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.